An interventional study of Whole milk and Nonfat milk in Obesity, Diabetes and Cardiovascular Diseases, sponsored by Boston Children's Hospital. Recruiting at 1 site in United States. Open to participants aged 9 Years to 12 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-08.
Sponsored by Boston Children's Hospital · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Obesity by Boston Children's Hospital — 2 open to participants now, 2 under way, none of them phase 3. Obesity · Boston Children's Hospital.
Among the 19 studies in Obesity by Boston Children's Hospital, this one is the 6th largest by planned enrollment of the 18 interventional ones that give a count, is the only one that started in 2022, is one of 19 with no phase, and was the 17th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →2 of the 19 studies in Obesity by Boston Children's Hospital are open now, in 1 country. Recruiting first, the newest first:
Boston Children's Hospital · Sites in United States
Ages 2–17
By country, each count listing its studies:
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 9 Years to 12 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2022.
This study's planned enrollment of 200 is above the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 123 across the 18 interventional studies. Of the 17 that completed or were terminated, 3 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
Boston Children's Hospital is the lead sponsor of 609 studies on the registry; 148 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 19 (59%) have results posted.
1 of the studies in Obesity by Boston Children's Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05464186Boston Children's HospitalEffects of Whole vs. Nonfat Milk Consumption on Body Composition in Children | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies in Obesity by Boston Children's Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the effects of whole vs. nonfat milk consumption on body composition, cardiometabolic disease risk factors, and dietary quality.
Background The optimal type of milk is a topic of much debate. Several recent observational studies indicate that consuming whole (full-fat), compared to reduced-fat milk, is associated with less weight gain and decreased cardiometabolic disease risk. The observed beneficial effect of consuming whole milk on body weight may be due to its greater satiety value, leading to consumption of fewer calories from other lower quality (e.g., sugary) foods. Mechanistic studies indicate that substitution of carbohydrate with certain saturated fatty acids in milk increases low-density lipoprotein cholesterol (LDL-C). However, this increase has been attributed to large, buoyant particles that are less atherogenic than small, dense particles; is accompanied by an increase in high-density lipoprotein cholesterol (HDL-C); and may not elevate overall risk compared to carbohydrate.
Specific Aims and Hypotheses
Design Randomized Controlled Trial. Participants (N=200, aged 9 to 12 years, BMI≥75th percentile) will be randomly assigned for 1 year to receive: 1) Whole milk, 3 cups/d or 2) Nonfat milk, 3 cups/d. To promote adherence to the interventions, the investigators will rely on home delivery of milk using methods consistent with previous successful studies.
Study Outcomes The primary outcome is change in fat mass measured by air displacement plethysmography (BodPod) at 3 time points (baseline and 6 and 12 months). To evaluate cardiometabolic disease risk factors, the investigators will obtain a plasma MetaboProfile®(LabCorp) that includes lipoprotein particle sizes and subfraction concentrations, novel measures of insulin-resistant dyslipoproteinemia and inflammation, and a conventional lipid profile. The investigators will also measure blood pressure.
For the Ancillary Study, outcomes include salivary cariogenicity (pH, flow, and buffering capacity); caries prevalence; dietary quality (cariogenic potential); and serum 25-hydroxyvitamin D.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
3 cups a day of whole milk for 1 year
Behavioral: Whole milk
3 cups a day of nonfat milk for 1 year
Behavioral: Nonfat milk
Weekly home delivery of whole milk, daily text messages, monthly virtual visits
Weekly home delivery of nonfat milk, daily text messages, monthly virtual visits
Fat mass
Primary outcome for the overall study, main outcome for Specific Aim #1, measured by air displacement plethysmography (BodPod)
Time frame: Change from start of trial (time of randomization) through end of trial (12 months)
Lean body mass
Measured by air displacement plethysmography (BodPod)
Time frame: Change from start of trial (time of randomization) through end of trial (12 months)
Percent body fat
Measured by air displacement plethysmography (BodPod)
Time frame: Change from start of trial (time of randomization) through end of trial (12 months)
Height
Linear growth
Time frame: Change from start of trial (time of randomization) through end of trial (12 months)
Body mass index (BMI)
Weight in kg divided by height in meters squared
Time frame: Change from start of trial (time of randomization) through end of trial (12 months)
Leptin
"Satiety" hormone, released by fat cells, measured by ELISA assay
Time frame: Change from start of trial (time of randomization) through end of trial (12 months)
Ghrelin
"Hunger" hormone, released primarily in the stomach, measured by ELISA assay
Time frame: Change from start of trial (time of randomization) through end of trial (12 months)
Insulin-like growth factor-1 (IGF-1)
Indicator of growth hormone action, measured by ELISA assay
Time frame: Change from start of trial (time of randomization) through end of trial (12 months)
Insulin-like growth factor-binding protein 3 (IGF-BP3)
Measured by ELISA assay
Time frame: Change from start of trial (time of randomization) through end of trial (12 months)
Lipoprotein insulin resistance (LPIR)
Main outcome for Specific Aim #2; a 6-component weighted score of triglyceride-rich, high-density, and low-density lipoprotein particle (TRL-P, HDL-P, LDL-P) sizes and subfraction concentrations (sum of large and very large TRL-P, large HDL-P, small LDL-P), measured by nuclear magnetic resonance spectroscopy
Time frame: Change from start of trial (time of randomization) through end of trial (12 months)
Triglyceride-rich lipoprotein particle (TRL-P) size
Measured by nuclear magnetic resonance spectroscopy
Time frame: Change from start of trial (time of randomization) through end of trial (12 months)
High-density lipoprotein particle (HDL-P) size
Measured by nuclear magnetic resonance spectroscopy
Time frame: Change from start of trial (time of randomization) through end of trial (12 months)
Low-density lipoprotein particle (LDL-P) size
Measured by nuclear magnetic resonance spectroscopy
Time frame: Change from start of trial (time of randomization) through end of trial (12 months)
Sum of large and very large TRL-P concentration
Measured by nuclear magnetic resonance spectroscopy
Time frame: Change from start of trial (time of randomization) through end of trial (12 months)
Large HDL-P concentration
Measured by nuclear magnetic resonance spectroscopy
Time frame: Change from start of trial (time of randomization) through end of trial (12 months)
Small LDL-P concentration
Measured by nuclear magnetic resonance spectroscopy
Time frame: Change from start of trial (time of randomization) through end of trial (12 months)
Large LDL-P concentration
Measured by nuclear magnetic resonance spectroscopy
Time frame: Change from start of trial (time of randomization) through end of trial (12 months)
Triglycerides (TG)
Part of conventional lipid profile
Time frame: Change from start of trial (time of randomization) through end of trial (12 months)
High-density lipoprotein cholesterol (HDL-C)
Part of conventional lipid profile
Time frame: Change from start of trial (time of randomization) through end of trial (12 months)
Low-density lipoprotein cholesterol (LDL-C)
Part of conventional lipid profile
Time frame: Change from start of trial (time of randomization) through end of trial (12 months)
Glucose
Measured enzymatically using hexokinase method
Time frame: Change from start of trial (time of randomization) through end of trial (12 months)
Insulin
Measured by electrochemiluminescence immunoassay
Time frame: Change from start of trial (time of randomization) through end of trial (12 months)
Insulin resistance
Measured by homeostasis model assessment (HOMA), using fasting glucose and insulin concentrations
Time frame: Change from start of trial (time of randomization) through end of trial (12 months)
Adiponectin - total and high molecular weight
Hormone released from fat cells, promotes insulin sensitivity and helps regulate blood glucose, measured by ELISA assay
Time frame: Change from start of trial (time of randomization) through end of trial (12 months)
Hemoglobin A1c (HgA1c)
Marker of blood glucose control, measured using a system based turbidimetric immunoinhibition
Time frame: Change from start of trial (time of randomization) through end of trial (12 months)
High-sensitivity C-reactive protein (hsCRP)
Indicator of chronic inflammation, measured by immunoturbidimetric assay
Time frame: Change from start of trial (time of randomization) through end of trial (12 months)
Interleukin-6 (IL-6)
Protein which stimulates synthesis of hsCRP, measured by ELISA assay
Time frame: Change from start of trial (time of randomization) through end of trial (12 months)
Fibrinogen
Protein involved in blood clotting, measured by immunoturbidimetric assay
Time frame: Change from start of trial (time of randomization) through end of trial (12 months)
Plasminogen activator inhibitor-1 (PAI-1)
Protein involved in blood clotting, measured by ELISA assay
Time frame: Change from start of trial (time of randomization) through end of trial (12 months)
Systolic blood pressure
Measured by auscultation
Time frame: Change from start of trial (time of randomization) through end of trial (12 months)
Diastolic blood pressure
Measured by auscultation
Time frame: Change from start of trial (time of randomization) through end of trial (12 months)
Salivary cariogenicity
(Ancillary Study) Risk for dental caries (cavities), measured using the GC Dental America Saliva-Check Buffer Kit (pH, flow, and buffering capacity)
Time frame: Change from start of trial (time of randomization) through end of trial (12 months)
Caries prevalence
(Ancillary Study) Assessed by clinical examination and digital radiograph (x-rays)
Time frame: Difference between start of trial (time of randomization) and end of trial (12 months)
Serum 25-hydroxyvitamin D [25(OH)D]
(Ancillary Study) Measured by a competitive electrochemiluminescence immunoassay
Time frame: Change from start of trial (time of randomization) through end of trial (12 months)
Pentadecanoic acid (C15:0)
Process measure, biomarker of milk fast consumption, fatty acid in red blood cell membranes which comes primarily from milk fat
Time frame: Change from start of trial (time of randomization) through end of trial (12 months)
Heptadecanoic acid (C17:0)
Process measure, biomarker of milk fast consumption, fatty acid in red blood cell membranes which comes primarily from milk fat
Time frame: Change from start of trial (time of randomization) through end of trial (12 months)
trans Palmitoleic acid (tC16:1ω-7)
Process measure, biomarker of milk fast consumption, fatty acid in red blood cell membranes which comes primarily from milk fat
Time frame: Change from start of trial (time of randomization) through end of trial (12 months)
Alternative Healthy Eating Index (AHEI)
Main outcome for Specific Aim #3, calculated using data from 24-hour dietary recalls
Time frame: Change from start of trial (time of randomization) through end of trial (12 months)
Milk intake
Process outcome, measured by 24-hour dietary recalls
Time frame: Change from start of trial (time of randomization) through end of trial (12 months)
Nutrient profile
Added sugars, saturated fat, fiber, calcium; measured by 24-hour dietary recalls
Time frame: Change from start of trial (time of randomization) through end of trial (12 months)
Food and beverage intake pattern
Vegetables, fruits, legumes, and sugar-sweetened beverages; measured by 24-hour dietary recalls (Ancillary Study) Frequency of consuming between-meal-sugar-containing foods or beverages and consumption of foods (grams) with a high cariogenic potential, measured by 24-hour dietary recalls
Time frame: Change from start of trial (time of randomization) through end of trial (12 months)
Plan to share: Yes — We will share de-identified IPD on Open Science Framework.
Supporting information: Study protocol, Analytic code
Time frame: The Study Protocol will be posted prior to enrollment of the first study participant. The IPD and Analytic Code for each peer reviewed manuscript from the study will be posted at the time of publication.
Access criteria: The data will be available to any interested party through Open Science Framework.
Started Dec 2022 (actual). Primary completion is estimated for Dec 2026, 48 months after the start.
Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 48 months is above that.
Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.